ProfileGDS5678 / 1416689_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 31% 32% 33% 35% 29% 31% 32% 32% 32% 14% 32% 32% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7482931
GSM967853U87-EV human glioblastoma xenograft - Control 22.7122631
GSM967854U87-EV human glioblastoma xenograft - Control 32.7326632
GSM967855U87-EV human glioblastoma xenograft - Control 42.6912633
GSM967856U87-EV human glioblastoma xenograft - Control 52.738835
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7431829
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7555431
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7098432
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6989232
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7182632
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.3318214
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7024532
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7186132
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7202832